Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Herrmann

Showing results (571-580 of 773) with videos related to

Pageof 78
Sort By:
The New England Journal of Medicine|June 23, 2001
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizationE J Topol, D J Moliterno, H C Herrmann, et al.
Cytotherapy|August 5, 2018
Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host diseaseAbel Trujillo-Ocampo, Hyun-Woo Cho, Amanda C Herrmann, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 22, 2014
Rationale, development, implementation, and initial results of a fast track protocol for transfemoral transcatheter aortic valve replacement (TAVR)Rebecca Marcantuono, Jacob Gutsche, Maureen Burke-Julien, et al.
JACC. Cardiovascular Interventions|August 20, 2018
The Effect of Post-Dilatation on Outcomes in the PARTNER 2 SAPIEN 3 RegistryRebecca T Hahn, Philippe Pibarot, Jonathon Leipsic, et al.
American Heart Journal|September 26, 2006
Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30)C Michael Gibson, Ajay J Kirtane, David A Morrow, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 18, 2017
Outcomes, readmissions, and costs in transfemoral and alterative access transcatheter aortic valve replacement in the US Medicare populationFenton H McCarthy, Danielle D Spragan, Danielle Savino, et al.
JACC. Cardiovascular Interventions|April 23, 2021
Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation: Results From the COAPT TrialRim Halaby, Howard C Herrmann, Zachary M Gertz, et al.
Herz|July 15, 2016
[Assessment of subjective physical well-being in heart failure : Validation of the FEW16 questionnaire]D Jahandar Lashki, C Zelenak, E Tahirovic, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 18, 2017
Cost and contribution margin of transcatheter versus surgical aortic valve replacementFenton H McCarthy, Danielle C Savino, Chase R Brown, et al.
The American Journal of Cardiology|April 13, 2015
Prognostic value of serial B-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial)Brian P O'Neill, Mayra Guerrero, Vinod H Thourani, et al.
Pageof 78

Showing results (571-580 of 773) with videos related to

Sort By:
Pageof 78
The New England Journal of Medicine|June 23, 2001
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizationE J Topol, D J Moliterno, H C Herrmann, et al.
Cytotherapy|August 5, 2018
Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host diseaseAbel Trujillo-Ocampo, Hyun-Woo Cho, Amanda C Herrmann, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 22, 2014
Rationale, development, implementation, and initial results of a fast track protocol for transfemoral transcatheter aortic valve replacement (TAVR)Rebecca Marcantuono, Jacob Gutsche, Maureen Burke-Julien, et al.
JACC. Cardiovascular Interventions|August 20, 2018
The Effect of Post-Dilatation on Outcomes in the PARTNER 2 SAPIEN 3 RegistryRebecca T Hahn, Philippe Pibarot, Jonathon Leipsic, et al.
American Heart Journal|September 26, 2006
Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30)C Michael Gibson, Ajay J Kirtane, David A Morrow, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 18, 2017
Outcomes, readmissions, and costs in transfemoral and alterative access transcatheter aortic valve replacement in the US Medicare populationFenton H McCarthy, Danielle D Spragan, Danielle Savino, et al.
JACC. Cardiovascular Interventions|April 23, 2021
Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation: Results From the COAPT TrialRim Halaby, Howard C Herrmann, Zachary M Gertz, et al.
Herz|July 15, 2016
[Assessment of subjective physical well-being in heart failure : Validation of the FEW16 questionnaire]D Jahandar Lashki, C Zelenak, E Tahirovic, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 18, 2017
Cost and contribution margin of transcatheter versus surgical aortic valve replacementFenton H McCarthy, Danielle C Savino, Chase R Brown, et al.
The American Journal of Cardiology|April 13, 2015
Prognostic value of serial B-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial)Brian P O'Neill, Mayra Guerrero, Vinod H Thourani, et al.
Pageof 78